CRBP Key Statistics, Chart & Performance
The current stock price of CRBP is 7.83 USD. In the past month the price decreased by -6.34%. In the past year, price decreased by -22.86%.
CRBP Technical Analysis
CRBP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CRBP. No worries on liquidiy or solvency for CRBP as it has an excellent financial health rating, but there are worries on the profitability.
CRBP Financial Highlights
Over the last trailing twelve months CRBP reported a non-GAAP Earnings per Share(EPS) of -5.51. The EPS decreased by -17.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -61.65% | ||
| ROE | -73.27% | ||
| Debt/Equity | 0 |
CRBP Forecast & Estimates
16 analysts have analysed CRBP and the average price target is 43.18 USD. This implies a price increase of 451.47% is expected in the next year compared to the current price of 7.83.
CRBP Ownership
CRBP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.39 | 394.886B | ||
| AMGN | AMGEN INC | 17.06 | 206.949B | ||
| GILD | GILEAD SCIENCES INC | 17.1 | 189.204B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.44 | 121.258B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.91 | 82.557B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.99 | 43.353B | ||
| INSM | INSMED INC | N/A | 31.961B | ||
| BIIB | BIOGEN INC | 13.22 | 29.513B | ||
| NTRA | NATERA INC | N/A | 28.022B | ||
| INCY | INCYTE CORP | 13.54 | 21.279B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CRBP
Company Profile
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. The company is headquartered in Norwood, Massachusetts and currently employs 28 full-time employees. The company went IPO on 2014-10-24. The firm has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.
Company Info
CORBUS PHARMACEUTICALS HOLDI
500 River Ridge Drive
Norwood MASSACHUSETTS 02062 US
CEO: Yuval Cohen
Employees: 28
Phone: 16179630103
CORBUS PHARMACEUTICALS HOLDI / CRBP FAQ
What does CORBUS PHARMACEUTICALS HOLDI do?
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. The company is headquartered in Norwood, Massachusetts and currently employs 28 full-time employees. The company went IPO on 2014-10-24. The firm has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.
Can you provide the latest stock price for CORBUS PHARMACEUTICALS HOLDI?
The current stock price of CRBP is 7.83 USD. The price increased by 5.95% in the last trading session.
What is the dividend status of CORBUS PHARMACEUTICALS HOLDI?
CRBP does not pay a dividend.
How is the ChartMill rating for CORBUS PHARMACEUTICALS HOLDI?
CRBP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is CRBP stock listed?
CRBP stock is listed on the Nasdaq exchange.
Would investing in CORBUS PHARMACEUTICALS HOLDI be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CRBP.